EMEA-001429-PIP01-13-M02

Key facts

Invented name
Besponsa
Active substance
inotuzumab ozogamicin
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0402/2017
PIP number
EMEA-001429-PIP01-13-M02
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of B cell acute lymphoblastic leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries
Pfizer Ltd  
Tel. +44 (0)1304 646607 
E-mail: pip_enquiries@pfizer.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating